

Table 11.6a
Immunosuppression Use for Induction, 1998 to 2007
Recipients with Heart Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	2,348	2,188	2,199	2,202	2,155	2,057	2,015	2,125	2,193	2,207
With Immunosuppression Info	2,318	2,138	2,148	2,152	2,119	2,024	1,974	2,056	2,120	2,135
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	16.9%	12.0%	9.4%	7.7%	7.0%	7.9%	7.2%	6.9%	4.7%	4.2%
OKT3	9.9%	11.1%	8.7%	8.6%	5.4%	4.6%	3.6%	3.2%	3.1%	3.2%
Thymoglobulin	0.0%	2.5%	6.9%	10.7%	16.2%	12.9%	15.7%	14.7%	18.2%	19.2%
Zenapax	2.9%	7.2%	8.8%	13.4%	11.4%	14.6%	15.7%	15.6%	14.5%	12.7%
Simulect	0.2%	2.5%	5.1%	5.2%	7.0%	9.3%	10.2%	13.6%	15.0%	14.2%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.9%	0.7%	1.7%	2.6%
No Induction Drugs Recorded	70.5%	65.7%	62.8%	56.4%	55.1%	52.9%	52.9%	47.8%	45.2%	46.1%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.